Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy

Human Mutation

Volumn 28, Issue 2, 2007, Pages 196-202

  Béroud, Christophe ^a   Tuffery Giraud, Sylvie ^a   Matsuo, Masafumi ^b   Hamroun, Dalil ^a   Humbertclaude, Véronique ^a   Monnier, Nicole ^c   Moizard, Marie Pierre ^d   Voelckel, Marie Antoinette ^e   Calemard, Laurence Michel ^f   Boisseau, Pierre ^g   Blayau, Martine ^h   Philippe, Christophe ⁱ   Cossée, Mireille ^j   Pagès, Michel ^k   Rivier, François ^k   Danos, Olivier ^l   Garcia, Luis ^l   Claustres, Mireille ^a  

^a UNIV MONTPELLIER   (France)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d CHU BRETONNEAU   (France)

^e TIMONE HOSPITAL   (France)

^f HÔPITAL DEBROUSSE   (France)

^g UNIVERSITÉ DE NANTES   (France)

^h Lab de Génétique   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l GÉNÉTHON   (France)

more..

Author keywords

BMD; DMD; Dystrophin; Multiple exon skipping; Muscular dystrophy

Indexed keywords

CREATINE KINASE; DYSTROPHIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; DATA BASE; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE DELETION; GENE MUTATION; HUMAN; MULTIPLE EXON SKIPPING; MUSCLE BIOPSY; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SYMPTOMATOLOGY; WESTERN BLOTTING;

ADOLESCENT; ADULT; CHILD; CODON, NONSENSE; COMPUTATIONAL BIOLOGY; DYSTROPHIN; EXONS; HUMANS; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; OPEN READING FRAMES; PHENOTYPE; SEQUENCE ANALYSIS, RNA; SEQUENCE DELETION;

EID: 33846924058     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20428     Document Type: Article

References (36)

1. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC. 2004a. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74:83-92.
2. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. 2004b. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11:1391-1398.
3. Anderson LV, Davison K. 1999. Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 154:1017-1022.
4. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM. 1991. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 49:54-67.
5. Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. 2000. UMD (Universal Mutation Database): a generic software to build and analyze locus-specific databases. Hum Mutat 15:86-94.
6. Beroud C, Hamroun D, Collod-Beroud O, Boileau C, Soussi T, Claustres M. 2005. UMD (Universal Mutation Database): 2005 update. Hum Mutat 26:184-191.
7. Bornemann A, Anderson LV. 2000. Diagnostic protein expression in human muscle biopsies. Brain Pathol 10:193-214.
8. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. 2003. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568-3571.
9. Crawford GE, Lu QL, Partridge TA, Chamberlain JS. 2001. Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Hum Mol Genet 10:2745-2750.
10. Fabbrizio E, Leger J, Anoal M, Leger JJ, Mornet D. 1993. Monoclonal antibodies targeted against the C-terminal domain of dystrophin or utrophin. FEBS Lett 322:10-14.
11. Fairbrother WG, Yeo CW, Yeh R, Goldstein P, Mawson M, Sharp PA, Burge CB. 2004. RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res 32(Web Server issue):W187-W190.
12. Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, Wilton SD. 2006. Induction of revenant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 4:3.
13. Fokkema IF, den Dunnen JT, Taschner PE. 2005. LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat 26:63-68.
14. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O. 2004. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306:1796-1799.
15. Herczegfalvi A, Toth C, Gyurus P, Morava E, Endreffy E, Fodor F, Mechler F, Laszlo A, Rasko I, Melegh B. 1999. Deletion patterns of dystrophin gene in Hungarian patients with Duchenne/Becker muscular dystrophies. Neuromuscul Disord 9:552-554. Hoffman EP, Brown RH Jr, Kunkel LM. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919-928.
16. Kapsa R, Kornberg AJ, Byrne E. 2003. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol 2:299-310.
17. Kobinger GP, Louboutin JP, Barton ER, Sweeney HL, Wilson JM. 2003. Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum Gene Ther 14:1441-1449.
18. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. 1987. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509-517.
19. Koenig M, Monaco AP, Kunkel LM. 1988. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53:219-226.
20. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng C, Muller CR, Lindlof M, Kaariainen H, de la Chapelle A, Kiuru A, Savontaus M-L, Gilgenkrantz H, Recan D, Chelly J, Kaplan J-C, Covone AE, Archidiacono N, Romeo C, Liechti-Gallati S, Schneider V, Braga S, Moser H, Darras BT, Murphy P, Francke U, Chen JD, Morgan C, Denton M, Greenberg CR, Wrogemann K, Blonden LAJ, van Paassen HMB, van Ommen GJB, Kunkel LM. 1989. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498-506.
21. Lenk U, Demuth S, Kraft U, Hanke R, Speer A. 1993. Alternative splicing of dystrophin mRNA complicates carrier determination: report of a DMD family. J Med Genet 30:206-209.
22. Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD, Chamberlain JS. 2005. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12:1099-1108.
23. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. 2005. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11:245-256.
24. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T. 2005. Systemic delivery of antisense oligoribonudeotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198-203.
25. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. 1988. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90-95.
26. Morrone A, Zammarchi E, Scacheri PC, Donati MA, Hoop RC, Servidei S, Galluzzi G, Hoffman EP. 1997. Asymptomatic dystrophinopathy. Am J Med Genet 69:261-267.
27. Nonaka I. 2004. [Muscular dystrophy, advances in research works and therapeutic trials]. Rinsho Shinkeigaku 44:901-904. [Japanese]
28. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS. 1995. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4:1251-1258.
29. Sironi M, Bardoni A, Felisari G, Cagliani R, Robotti M, Comi GP, Moggio M, Bresolin N. 2001. Transcriptional activation of the non-muscle, full-length dystrophin isoforms in Duchenne muscular dystrophy skeletal muscle. J Neurol Sci 186:51-57.
30. Sironi M, Menozzi G, Riva L, Cagliani R, Comi GP, Bresolin N, Giorda R, Pozzoli U. 2004. Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res 32:1783-1791.
31. Surono A, Van Khanh T, Takeshima Y, Wada H, Yagi M, Takagi M, Koizumi M, Matsuo M. 2004. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of Duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum Gene Ther 15:749-757.
32. Takeda S. 2004. [Current status and perspective of gene therapy on dystrophic animal model]. Rinsho Shinkeigaku 44:911-913. [Japanese]
33. Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB. 2004. Systematic identification and analysis of exonic splicing silencers. Cell 119:831-845.
34. Wilton SD, Dye DE, Laing NG. 1997. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve 20:728-734.
35. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y, Takeda S. 2004. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 10:821-828.
36. Zhang XH, Chasin LA. 2004. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 18:1241-1250.